23 - 24 June 2025
Congress Center Basel, Basel, Switzerland

Pushing Traditional Boundaries in Pharmaceutical Science by Accelerating the Discovery & Development of Novel Therapeutics

23 - 24 June 2025
Congress Center Basel, Basel, Switzerland

Explore Discovery & Development Europe 2025: Guiding Biopharma From Target Identification To Clinical Candidate

Connect & collaborate with 1000+ leaders in biology and chemistry at the renowned Discovery & Development Summit in Basel, where we provide a platform to help you make informed pipeline decisions in early R&D & accelerate the route from target identification to novel clinical candidate, ultimately increasing the number of life-saving treatments for those with critical illnesses.

Together with Formulation & Delivery, benefit from an event supporting you to identify potential formulation & delivery bottlenecks and issues before they arise and promoting collaboration to ensure the development of optimised drug products. 

Discovery Development Exhibition Hall

Explore the Discovery & Development Europe 2025 Programme

NextGen Biomed 2025

Advancing Therapeutic Innovation Through Multi-Omics Research  

NextGen Omics & Spatial Biology connects thought leaders, researchers, and experts with pharmaceutical & biotech representatives to discuss the latest innovations across the fields of multi-omics. 

There are three dedicated programmes running across two full days, which together will explore multi-omics from technological development to therapeutic applications and analysis, making this a must-attend event for anyone working in clinical diagnostics, single cell & spatial biology. 

Hear from past attendees of last year's Biologics 2024 conference

Explore the NextGen Omics & Spatial Biology US 2025 Programme

Antibody Society

NextGen Biomed 2025 is supported by our
Scientific Programme Partner The Antibody Society

D&D About Square Button

About

Discover more about our ecosystem of channels for the discovery R&D community

D&D Europe 2025 Attend Button

Attend

Be part of the new wave of development R&D innovation

Partner Image

Partner

Showcase your offering to leading pharma and biotech decision makers

D&D Europe 2025 Whats On Button

What's On

Explore dynamic panels, engaging roundtables, and hands-on workshops

Discovery & Development Europe 2025 Programme Highlights

Explore dynamic panels, engaging roundtables, and hands-on workshops designed to drive innovation and foster collaboration in Drug Discovery, Formulation and Delivery including: 

Drug Discovery & Automation Programme - Key Themes

Panel Discussion: Technological Advancements For Novel Target Discovery

  • Application of new technologies in identifying therapeutics for novel or currently undruggable targets
  • Utilising AI/ML
  • Challenges & future opportunities

 

Panellists include Giovanni Spagnolli, Chief Technology Officer, Sibylla Biotech, Ian Roberts, Senior Director, Digital Biology, Healx & Zoran Rankovic, Director, Center for Protein Degradation, The Institute of Cancer Research

Panel Discussion: Novel Platforms & Techniques To Improve Hit Identification

 

•    Optimising Hit discovery
•    Minimising false positives
•    Integration of techniques

 

Moderated by Jonathan Hopper, Vice President Platforms & Founder, OMass Therapeutics

Panel Discussion: Fostering Partnerships & Collaboration In 2025 – as part of our newly introduced Early-Stage R&D Innovation Programme

 

  • Emerging technologies & techniques
  • Cross-sector partnership
  • Open innovation

 

Moderated by Alexander Natz, Secretary General, EUCOPE & panellists from Cicio Holdings, BioAge Labs, European Commission, Pfizer & Business Region Gothenburg

Panel Discussion: Breakthrough Biotech: How Research Leaders Fund The Next Big Idea

 

  • How research leaders identify and support fundable biotech innovations
  • Overcoming early-stage funding gaps in biotech startups
  • The role of research partnerships with pharma, VCs, and industry in startup success
  • What startups can learn from research-backed biotech wins

 


Panellists include Christoph Rösli, Director of Research Bern, CSL Behring & Member of the Selection Board, BaseLaunch; David Jenkinson, Head of Childhood Cancer Translational Challenge, LifeArc; David Dexter, Director of Research, Parkinsons UK 

Fireside Chat: Impact of AI & Big Data in Drug Discovery & Development

 

Panel Discussion: Translational Studies to Support Better Drug Design

  • Bridging the gap between pre-clinical & clinical research
  • Biomarkers & AI/ML in translational research

 

Moderated by Philippe Marc, Executive Director, Global Head of Integrated Data Sciences, Novartis

Panel Discussion: Fostering Collaboration To Accelerate Neurodegenerative Disease Research


•    Pharma, biotech & academic partnerships
•    The need for innovation, data & technology in CNS research
•    Challenges to be solved through collaboration 

Moderated by Emma Mead, Chief Scientific Officer, Alzheimer’s Research UK Oxford Drug Discovery Institute, University of Oxford. Panellists include Knut Biber, Research Fellow & Head of Glial Biology Team, AbbVie; Sarah Jolly, Principal Scientist, LifeArc; Michael Johnson, Professor of Neurology & Genomic Medicine, Imperial College London


Day 2 Breakfast Workshop - LifeArc: Biomarkers In Neurodegenerative Diseases: From Detection To Progression - Are Blood -Based Biomarkers Enough?

  • Beyond blood-based biomarkers?
  • Are we any closer to a solution?
  • Application of AI/ML

Moderated by Manuela Cerina, Scientific Director – Neurodegeneration, LifeArc & Giovanna Lalli, Director of Strategy & Operations, LifeArc

Panel Discussion:
Automation & Robotics In Drug Discovery & Development – Where Are We Now? 


•    Impact of automation 
•    AI/ML  
•    Robotics in lab processes

Moderated by Rekha Lakshmanan, Global Head of Data Office, AstraZeneca

Panellists include: James Love, Vice President Cross Modalities Workflows, Novo Nordisk, Sarah Trice, COO & Head of US Operations, XtalPi & Tom Kissling, pRED Lab Automation Partner, Roche

Day 2 Breakfast Workshop: SiLA & AnIML Splash


•    Splash! Is a unique event for every digital lab enthusiast. It combines an educational part with a hands-on session to try out standards in action. Pick up the details on the popular SiLA and AnIML standards, understand how they work and where you can put them to use. Our hands-on session lets you experience the standards in action firsthand. We’re bringing real and cloud-based instruments and lots of example data sets 
•    Feel free to bring an instrument or your own data

Formulation and Delivery Programme - Key Themes

Panel Discussion: Moving Beyond Oral Delivery

 

•    Nanoparticles
•    Inhalation
•    Transdermal
•    Developments with Oral Delivery

Moderated by Sandor Batkai, Life Science Consultant, Former, Head of Medical Research and Intelligence, Cardior Pharmaceuticals

Panellists include Shadi Farhangrazi, Chief Executive Officer, S.M. Discovery Group, Joël Richard, Executive Head, Product Development, DBV, Kamalinder Singh, Professor of Pharmaceutical, Technology & Drug Delivery, Karsten Mäder, Professor, Martin Luter University Halle-Wittenberg

Panel Discussion: AI/ML & Novel Technologies In Formulation & Delivery

  • Applications of AI/ML in formulation and delivery
  • AI-driven approaches to optimise dosage forms
  • Novel delivery technologies
  • AI/ML for personalised formulations

 

Moderated by Shilpa Thosar, CMC/Regulatory CMC Executive, Former Executive Director, Cara Therapeutics

Roundtable: Discovery And Delivery Of Therapeutics Across The Blood Brain Barrier – Where Are We Now?

  • Brain shuttle platform
  • Monocytes
  • Microbubbles

 

Moderated by Shadi Farhangrazi, Chief Executive Officer, S.M. Discovery Group

Key Event Highlights

An unmissable journey awaits you: from award winning speakers and insightful workshops, to an exclusive gala dinner. Discover the moments that will transform your Discovery & Development experience. 

Who is Speaking at Discovery & Development Europe 2025?

Andreas Gryczke
Director, Process Engineering,
AbbVie
Banurekha Lakshmanan
Global Head of Data Office,
AstraZeneca
Emma Mead
Chief Scientific Officer, Oxford Drug Discovery Institute,
University of Oxford
Heinrich Haas
Chief Technology Officer,
Neovacs
Karin Conde-Knape
Senior Vice President Global Drug Discovery,
Novo Nordisk
Morten Grunnet
Vice President, Head of Neuroscience,
Lundbeck
Philippe Marc
Executive Director, Global Head of Integrated Data Sciences,
Novartis
Shadi Farhangrazi
Chief Executive Officer,
S.M. Discovery Group
Sorina Morar-Mitrica
Director Science &Technology,
Novartis
Stephen Pham
Senior Vice President, Product Development,
Avalyn Pharma Inc.
Ulrich Betz
Senior Vice President Innovation,
Merck
Vineeta Tripathi
Chief Executive Officer,
Vitarka Therapeutics
Aaron Smith
Associate Director,
AstraZeneca
Abhishek Choudhary
Principal Data Engineer,
Bayer
Abi Heath
Patent Attorney & Counsel,
Kilburn & Strode
Alain Martelli
Director External Science and Innovation, France,
Pfizer
Alexander Natz
Secretary General,
EUCOPE
Amal Ali Elkordy
Professor,
University of Sunderland
Amardeep Singh Bhalla
Executive Director,
Regeneron
Andreas Bernkop Schnurch
Professor,
University of Innsbruck
Andrew Woodhead
Head of Chemistry,
Astex Pharmaceuticals
Andrew Ledgard
Senior Scientist,
Recursion
Andy Pike
Senior DMPK Discovery and Development Lead, Director,
AstraZeneca
Anna-Pia Papageorgiou
Policy Officer, Health Innovations & Ecosystems, DG Research & Innovation,
European Commission
Antonia Stepan
Section Head, Medicinal Chemistry,
Roche
Arianna Sabò
Head of Research & Discovery,
QUANTRO Therapeutics
Arne Skerra
Professor,
Technische Universität München
Benedict Cross
CTO,
PhoreMost Ltd
Burkhard Schäfer
Managing Director & Director at SiLA,
SiLA
Carol Mulrooney
Principal Investigator, Cheminformatics,
GSK
Christine Maurer
Scientific Associate Director Biotransformation,
Merck & Cie KmG
Christoph Rösli
Director Research,
CSL Behring & BaseLaunch
Chuang Kee Ong
Director Data Product,
GSK
Cornelis Van Tilburg
Head of KiTZ CTU,
Hopp-Kindertumorzentrum Heidelberg
Covadonga Paneda
Chief Operating Officer,
Altamira Therapeutics
Dan Hardy
Chief Executive Officer,
Microsol Science
Daniel Tondera
Head of Biology,
Pantherna Therapeutics
David Jenkinson
Head of Childhood Cancer Translational Challenge,
LifeArc
David Dexter
Research Director,
Parkinson's UK
David Gnutt
Vice President, Complex In Vitro Lead, RED Cardiovascular, Renal and Immunology,,
Bayer
Davide Gianni
Senior Director,
AstraZeneca
Delphine Heenen
Kicker In Chief Managing Director,
KickCancer
Diana Knapp-Bühle
Associate Director and DMPK Lead,
Merck Healthcare KGaA
Duane Schulthess
CEO,
Vital Transformation
Eric Lorent
Senior Scientist,
Sanofi
Estelle Beguin
Director of Technology Research,
Ethris
Fabrizio Dissegna
Formulator,
Chiesi
Farshad Ramazani
Senior Expert Science & Technology,
Novartis
Florian Ries
Senior Scientist,
AbbVie
Gergely Toth
Chief Executive Officer & Chief Scientific Officer,
Cantabio Pharmaceuticals
Giovanni Spagnolli
Chief Technology Officer,
Sibylla Biotech
Giovanni Ca'Zorzi
Strategic Communications,
Cohesion Bureau
Heena Khatter
Principal Scientist,
Roche
Heide Düvel
Scientific Associate Director DMPK,
Merck Healthcare KGaA
Hemachandran Kannan
Director of the AI Centre,
Woxsen University
Ian Roberts
Director of Therapeutic Technology,
Healx
Iris Valtingojer
Sanofi Childhood Cancer R&D CSR Lead,
Sanofi
Jack Doolan
Investigator,
GSK
James Dale
Director of Drug Discovery,
PharmEnable Therapeutics
James Love
Vice President, Automation and Process Optimization,
Novo Nordisk
James Connell
Scientific Director - Translational Matrix Group,
LifeArc
Jens Twellmeyer
Associate Director Science & Technology,
Novartis
Jitendra Kumar
Lead Scientist,
Entos Pharmaceuticals
Joao Seixas
CEO,
TargTex
Joel Richard
Executive Head of Product Development,
DBV
Johanna Roostalu
Director, Therapeutics, Venture Creation,
BioInnovation Institute
Jonathan Hopper
Vice President, Platforms & Founder,
OMass Therapeutics
Jörg Berghausen
Associate Director,
Novartis
Jose-Carlos Gomez-Tamayo
Scientist,
Janssen Pharmaceutical Companies of Johnson & Johnson
Kamalinder Kaur Singh
Professor of Pharmaceutical Technology and Drug Delivery,
University of Central Lancashire
Karsten Maeder
Professor,
Martin Luther University Halle-Wittenberg
Kelly Zalocusky
Senior Director of Computational Biology, Neuroscience,
Recursion Pharmaceuticals
Knut Biber
Research Fellow & Head of Glial Biology Team,
AbbVie
Konstantinos Gkatzis
Cardiovascular Team Lead & COO at Myrtil Biotechnologies,
Ksilink
Kristina Levan
Business Developer,
Business Region Gothenburg
Krisztian Kaszas
Sr Scientist, Assay Automation,
Johnson & Johnson
Lars van der Veen
Chief Scientific Officer,
ionctura
Laura Gasparini
Director -Tau pathobiology,
AbbVie
Lene Gerlach
Venture Partner, Founder of Women in Life Science Denmark (WiLD),
Hadean Ventures
Lubor Gaal
Chief Financial Officer & Chief Business Officer,
Circio
Maeve Caldwell
Professor in Neuroscience, Physiology,
Trinity College Dublin
Manuela Cerina
Scientific Director of Neurodegeneration,
LifeArc
Marcos Costa
Principal Scientist,
Roche
Maria Levitin
Director of RNA Oligonucleotide Delivery, Genetic Medicine,
Grünenthal GmbH
Marie-Christine Pardon
Assistant Professor in Translational Neuroscience,
University of Nottingham
Marius Lutz
Scientist, High-Throughput Experimentation, Chemical Reaction Screening,
Hoffmann La Roche Ltd
Mark Chiu
President & Chief Scientific Officer,
Tavotek BioTherapeutics
Markus Hierl
Principal Associate,
Hoffmann La Roche Ltd
Martinus Capelle
Scientific Director,
Johnson & Johnson
Meike Harms
Lead Scientist,
Merck
Meiling Li
Technical project leader,
Roche
Michael Johnson
Professor of Neurology and Genomic Medicine,
Imperial College London
Michele Cleary
President & Chief Scientific Officer,
Advancium Health Network
Miroslav Cik
Senior Principal Research Scientist,
Abbvie
Moein Moghimi
Professor of Nanomedicine and Pharmaceutics, School of Pharmacy,
Newcastle University
Naisha Shah
Vice President of Data Science,
BioAge Labs
Natasha Drapeau
Managing Director & Co-Founding Senior Partner, Cohesion Bureau,
Cohesion Bureau
Paulina Kolasinska-Zwierz
Principal Scientist,
Alchemab
Peng Leong
CBO and Head of Brain Aging,
Bioage labs
Phil Noble
Head of Single B Cell Antibody Discovery,
UCB Pharma
Philip Hewitt
Global Head of Early Investigative Toxicology,
Merck
Poppy Winlow
Senior Research Scientist,
AstraZeneca
Rainer Wilcken
Director, Computational Chemistry,
Flare Therapeutics Inc
Rajaa Sukhun
Senior Director of Research DMPK,
Cytokinetics
Ramesh Kashi Kashi
Senior Scientific Advisor,
EPOK Therapeutics
Rick Ewing
VP, Head of Chemistry,
Rapafusyn Pharmaceuticals
Robin Loving
Chief Scientific Officer,
Salipro Biotech AB
Roderick Beijersbergen
Head of NKI Genomics Core Facility & Professor of Functional Genomics,
The Netherlands Cancer Institute
Sabine Kuratli
CMC Lead,
CEPI
Sagar Chandekar
Global Medical Manager- Neurodegenerative Diseases,
Novo Nordisk
Sam Daems
Portfolio Principal,
Waterland Private Equity
Sandor Batkai
Freelance Consultant,
Formerly Cardior Pharmaceuticals
Sarah Jolly
Principal Scientist,
LifeArc
Shayoni Dutta
Data Science Manager,
GSK
Shilpa Thosar
Former Director,
Cara Therapeutics
Shreenivasa Rajanala
VP, Global Head of Data Science and Advanced Analytics,
Bayer
Simone Vecchi
Associate Director - Drug Product Development Scientific Integrator,
Johnson & Johnson Innovative Medicine
Simone Hornemann
Director UZH CRISPR Screening Hub,
University Hospital Zurich
Sonja Kühn
Head of Structural Biophysics and Computational Chemistry PA, Research,
Servier
Sophie Janbon
Director,
AstraZeneca
Steen Krogsgaard
Scientific Automation Director,
Novo Nordisk
Stefan Schiesser
Director of Medicinal Chemistry,
AstraZeneca
Stephanie Harlfinger
Senior Director, Global Head NCE DMPK,
Merck & Cie KmG
Supriyadi Hafiz
Senior Scientist,
Merck
Suruchi Vishwasrao
Senior Scientist,
Merck Life Science Pvt. Ltd.
Sven Verguts
Associate Director, Emerging Biotech & ATMPs,
Merck
Tamara Maes
Former Chief Scientific Officer & Founder,
Oryzon Genomics
Tanvir Tabish
Director, Early Formulation Development,
AstraZeneca
Thanneer Malai Perumal
Senior Principal Scientist,
Hoffmann La Roche Ltd
Thomas Von Erlach
Chief Scientific Officer,
Vivtex
Tjasa Vrlinic
Principal Investigator,
Medincell
Tom Kissling
pRED Automation Partner & Director at SiLA,
F. Hoffmann-La Roche AG
Tomasz Ratajczak
Formulation Expert,
Polpharma
Toria Legh-Land
Computational Pharmaceutics Lead,
Microsol
Trond Ulven
Professor,
Copenhagen University
Valentina Romeo
Principal Scientist & Group Leader,
Roche
Varun Kushwah
Principal Scientist,
RCPE
Vik Reebye
Head of Academic Partnership,
MiNA Therapeutics
Virginia Ballotta
New Ventures Manager,
BaseLaunch
Vladimir Talibov
Associate Principal Scientist,
Sprint Bioscience
Yi Sun
Associate Professor,
Technical University of Denmark
Zeeshan Ahmad
Reader in Pharmaceutics and Drug Delivery,
University of Manchester
Zhi Yao
Principal Scientist,
LifeArc
Zhizhou Fang
Associate Scientific Director in vitro DMPK,
Merck Healthcare KGaA
Zoran Rankovic
Professor of Chemical Biology, and Director of the Centre for Protein Degradation,
The Institute of Cancer Research
f9d83b55-ff87-4538-a4e2-f67b63da4765-2-5668375logo-Axion-Logo_Tagline_2022

 

Good number of 1-1 meetings with relevant people. Very happy with the networking process and the Oxford Global team are very nice and service minded.


Regional Sales Director
AxionBio

5a563b71-261f-4b78-a13b-5b4890a6b41d-2-5668375logo-Copy-of-Arctoris-blue-logo-1-Transparent

 

Absolutely outstanding conference attracting large pharma and aspiring biotechs. Oxford Global are excellent, the food is outstanding and the preset meetings are informal and impactful

Vice President of Business Development
Arctoris

Novalix Logo

 

The organisation was perfect. Good mix between excellent scientific presentations and network opportunities.


Pharmacology Associate Director
Novalix

novartis-logo

 

This was my first time at the conference and it was a great experience. Very well organized conference and I learned a lot and made valuable connection - Thank you Oxford Global.


Senior Principal Scientist

Novartis

Interested in Sponsoring NextGen Omics & Spatial Biology US 2025?

Become a driving force in accelerating the next generation of multi-omics-based treatments. NextGen Omics & Spatial Biology US offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, & academic experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, & collaborate with the community shaping the future of genomic medicine today.

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

Interested in Sponsoring Discovery & Development Europe 2025?

Become a driving force in accelerating the volume of safe, effective first-in-class drugs to reach patients. Discovery & Development offers a unique platform to enhance your brand visibility and connect with thousands of biopharma decision-makers. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the innovators shaping the future of R&D today

New Opportunities

The Start-up Zone

Are you developing a cutting-edge therapy, platform or technology? Our Start-Up Zone is designed to support emerging companies looking to increase their visibility, find potential partners or early adopters, and meet their investment goals – connecting them with our community of pharma, investors, and mid-to-large size biotechs.

Located in the Exhibition Hall, the Start-Up Zone allows therapeutic pioneers to showcase their approach, conduct invaluable 1:1 meetings and deliver a quick-fire pitch.

There are two options, based on the size of your organisation with prices starting from €1800. 

For further information and to get started submit the application form below.

Criteria:

The Start-Up Zone is designed for therapeutic start-ups, academic spin-outs, and early-stage technology/service providers.

 

To be eligible for inclusion, you must meet the following criteria:

 

•    0 – 5 years operating
•    0 – 30 employees
•    Pre-Series A funding


What you will receive:

  • 1 full conference pass
  • 10-minute pitch on the Start-Up Stage
  • 1x1m space in Start-Up Zone for own partnering meetings; cocktail table provided, start-up to bring 1x pull-up banner
  • Logo featured on website & event platform as a participating start-up
  • Ability to arrange 1:1 meetings via the congress app

 

2025 Young Scientist Awards (YSA) for Best Poster Presentation

The NextGen Biomed Young Scientist Awards include the best poster presentation award and are intended to honour an outstanding individual performance for a scientific work by a PhD student, PostDoc or early career scientist.

Please submit your poster presentation by no later than 13th January 2025 in the below category:

  • Protein/Antibody Engineering
  • Bioanalysis & Characterisation
  • Next Generation Biotherapeutics
  • Peptides Chemistry & Therapeutics
  • Oligonucleotides Chemistry & Therapeutics
  • Sustainable Chemistry & Manufacturing
  • Student (PhD), PostDoc or early career scientist under 35 years of age. Proof must be provided via an active student ID card or a copy of status
  • Applicants must be the first AND presenting author of the submitted paper and register for the meeting by 13th January 2025
  • ONLY ONE YSA submission per person will be accepted. If authors submit multiple abstracts for consideration for the YSA, only one abstract will be taken into consideration for the YSA

Applicants must follow the procedure as follows: 

  • Register and submit an abstract by 13th January 2025 using the registration link to the left on this page 
  • Once registered you will be provided with the online abstract submission form 
  • Prepare the poster or platform and present it (The poster presenter should be at the poster during all breaks.) 
  • The 3 winners with the highest scores will be announced at the Networking Drinks on the second day of the event 
  • The winners’ 10-minute oral presentations will take place during the networking drinks on day 2 

The platform or poster presentation will be evaluated by senior scientists (consisting of our speaking and steering group committee for the NextGen Biomed series) on the basis of originality of the approach and quality of the work (e.g. appropriate methodology, interpretation of results, conclusiveness). All participants will receive the scoring and comments after the annual meeting via email.

The 3 winners receiving the highest scores will be announced at the Networking Drinks on the Day 2 and will be given a trophy as well as £1,000 contribution towards travel costs. Oxford Global will also provide winners with PLUS Pass – 12 months access to our content platform providing access to on-demand presentations, exclusive reports and highlights. 

Plan Your Visit

Congress Center Basel
Messeplatz 21, CH-4058 Basel

By Rail

Basel is an international rail hub with direct ICE, IC and EC connections to Germany, Austria, Italy, France and the Benelux countries. Messe Basel can be reached in five to ten minutes from the three railway stations in Basel: SBB (Switzerland), SNCF (France) (Frankreich) and DB (Badischer Bahnhof, Germany)

By Tram

From the SBB/SNCF railway station, it’s a ten-minute journey on the No. 1 or 2 Tram to the “Messeplatz/Exhibition Square” stop where Messe Basel and the Congress Center are located. From Badischer Bahnhof railway station, “Messeplatz/Exhibition Square” is the second stop on the No. 2 or 6 tram.

By Air

EuroAirport Basel-Mulhouse-Freiburg is 15 minutes by car from Messe Basel. Basel municipal transport’s No. 50 bus additionally provides a straightforward connection from the airport to the SBB/SNCF railway station. From there, tram No. 1 or 2 will take you directly to Messeplatz/Exhibition Square. From Zurich Airport a direct rail connection will bring you to the SBB/SNCF railway station in Basel in less than an hour. For further information including a map and full directions, please visit: https://www.messe-basel.com/en/about-us/getting-to-messe-basel/

By Car

Basel is located at the point where the Swiss, German and French motorway networks all meet. The exhibition and congress site has its own direct link to the A2 motorway. The “Messe” exit will take you straight to the Messe Basel car park with its 1,200 parking spaces.

Oxford Global has secured a number of bedrooms at the Basel Marriott Hotel at a reduced conference rate: 

 

  • Sunday 22nd June 2025 – £265 (Including Breakfast & City Tax)
  • Monday 23rd June 2025 – £265 (Including Breakfast & City Tax)
    *Please note: £30 supplement is applicable for double occupancy

 

Should you wish to book a room, please email help@oxfordglobal.com

 

The final cut-off date to book bedrooms is Monday 2nd June 2025 – any bookings after this date are subject to availability and rates. Please note that any cancellations within 14 days prior to arrival are subject to full cancellation charges.

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2025, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Discovery & Development Europe 2025 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.

Interested in Discovery & Development Europe 2025?